# Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

> **NCT00871741** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Tetanus
- Poliomyelitis
- Neisseria Meningitidis
- Haemophilus Influenzae Type b
- Diphtheria
- Acellular Pertussis
- Hepatitis B

## Interventions

- **BIOLOGICAL:** GSK2202083A vaccine
- **BIOLOGICAL:** Infanrix hexa
- **BIOLOGICAL:** Menjugate

## Key facts

- **NCT ID:** NCT00871741
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-01
- **Primary completion:** 2009-06-25
- **Final completion:** 2009-06-25
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871741, "Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00871741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*